Experience with a higher impedance, fixed helix, steroid-eluting pacing lead. The SWEET PICOTIP Rx Study Group.
A higher impedance, steroid-eluting pacing lead was studied in a multicenter trial. A total of 132 leads were implanted in 61 patients and the electrical characteristics were compared with historical controls. The study lead had a lower pacing threshold at 3 months, 0.72 +/- 0.33 versus 1.29 +/- 0.82 in the atrium and 0.71 +/- 0.25 versus 1.52 +/- 0.52 in the ventricle (P < 0.01 for both). Impedance was significantly higher in the study lead, 923 +/- 133 versus 719 +/- 109 in the atrium and 980 +/- 235 versus 664 +/- 104 in the ventricle (P < 0.01 for both). Sensing was similar for both leads. The study lead's higher impedance values and low pacing thresholds combine to reduce pacing system energy requirements.
Division of Cardiology, Genesis Medical Center, Davenport, Iowa, USA. Giudici@CVMedPC.com
M C
MC
Giudici
M
M
Lee
S
S
Higgins
G R
GR
West
A K
AK
Moeller
J B
JB
Decker
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000628:therapy; D016022:Case-Control Studies; D003907:Dexamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017097:Electric Impedance; D004567:Electrodes, Implanted; D004867:Equipment Design; D005260:Female; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial
D003907:Dexamethasone; C018038:dexamethasone acetate